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Abstract
Background: Hip arthroplasties is one of the most frequent surgical procedures in Spain and are conducted
mainly in elderly subjects. We aim to analyze changes in incidence, co-morbidity profile, length of hospital stay
(LOHS), costs and in-hospital mortality (IHM) of patients undergoing primary total hip arthroplasty (THA) over an
8-year study period in Spain.
Methods: We selected all surgical admissions in individuals aged ≥40 years who had received a primary THA
(ICD-9-CM procedure code 81.51) between 2001 and 2008 from the National Hospital Discharge Database.
Age- and sex-specific incidence rates, LOHS, costs and IHM were estimated for each year. Co-morbidity was
assessed using the Charlson comorbidity index.
Multivariate analysis of time trends was conducted using Poisson regression. Logistic regression models were
conducted to analyze IHM.
Results: We identified a total of 161,791 discharges of patients having undergone THA from 2001 to 2008. Overall
crude incidence had increased from 99 to 105 THA per 100.000 inhabitants from 2001 to 2008 (p < 0.001). In 2001,
81% of patients had a Charlson Index of 0, 18.4% of 1-2, and 0.6% > 2 and in 2008, the prevalence of 1-2 or
>2 had increased to 20.4% and 1.1% respectively (p < 0.001). The mean LOHS was 13 days in 2001 and decreased
to 10.45 days in 2008 (p < 0.001). During the period studied, the mean cost per patient increased from 6,634 to
9,474 Euros. Multivariate analysis shows that from 2001 to 2008 the incidence of THA hospitalizations has
significantly increased for both sexes and only men showed a significant reduction in IHM after THA.
Conclusions: The current study provides clear and valid data indicating increased incidence of primary THA in
Spain from 2001 to 2008 with concomitant reductions in LOHS, slight reduction IHM, but a significant increase in
cost per patient. The health profile of the patient undergoing a THA seems to be worsening in Spain.
Background
Multiple studies have documented significant qualitative
and quantitative improvements in physical function and
health related quality of life after total hip arthroplasty
(THA) surgery [1-4]. THA surgery is highly successful
in relieving pain and has demonstrated to be a cost-
effective and durable procedure [1-4]. Recent reports
based on National Arthroplasty Registries show that the
overall 10-year survival of all THA is over 90% [5,6].
Collecting data about hospitalizations for THA is
important at a country level to evaluate the incidence,
patient characteristics and outcome of the surgery in
variables such as length of stay (LOHS), complications,
mortality and burden of disease [7]. Surveys from the
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tinued growth in the use of THA over the last decades
[7-11]. The demand for hip replacement is likely to
increase as the result of ageing populations and because
the extension of the age range for this treatment [7-11].
Current projections for the United States suggest that
from 2005 to 2030 the number of THA will increase by
174%, to nearly 600,000 procedures per year [11].
Liu et al found that the LOHS after a THA has
decreased from an average of 8.7 days in 1990-4, to
5.2 days in 1995-9, and to 4.5 days in the most recent
time period studied (2000-4). In addition, in-hospital
mortality rate has also decreased (0.33% in 1990-4 to
0.29% in 2000-2004) in different countries [7,9,10]. In
fact, the economic burden of THA surgery is high, con-
stantly increasing and shows great variation between
countries [12,13].
Comparisons of THA rates and outcomes between
countries could provide information that would help to
understand the possible differences and would also aid
for planning the provision of healthcare services [14]. In
the absence of a domestic joint replacement registry, the
discharge database provides a large alternative informa-
tion source to describe and analyze the trends and char-
acteristics of THA at a national level [13-15]. Therefore,
the aim of this study was to analyze national representa-
tive hospital discharge data, collected from 2001 to
2008 years, to elucidate changes in the incidence,
comorbidity profiles, LOHS, costs and in-hospital mor-
tality of patients undergoing primary THA in Spain over
a 8-year study period.
Methods
According to the Spanish Health System Organization,
each physician must declare, at the time of discharge of
each hospitalization all diagnoses and procedures per-
formed, using the code of the International Classification
of Disease, 9th revision (ICD-9CM). This information is
collected by the Spanish National Hospital Database,
namely Conjunto Minimo Basico de Datos (CMBD) that
compiles all the public and private hospital data covering
hence more than 95% of hospital discharges [16]. The
CMBD database includes patients’ variables (sex, date of
birth), date of admittance, date of discharge, discharge
destination (home, decease or other health/social institu-
tion), up to 14 discharge diagnosis and up to 20 proce-
dures performed during the admission.
We selected all surgical admissions (elective or emer-
gency admissions) in women and men with 40 years or
over, who received a primary THA procedures (ICD-9-
CM procedure code 81.51) during 2001-2008 year period.
We calculated the yearly age- and sex-specific incidence
rates by dividing the number of cases per year per sex and
age group, with the corresponding number of person in
that population group according to the National Institute
of Statistics (INE) reported at December 31 of each year
[17]. The incidence rates were expressed in terms of
100,000 inhabitants. The proportion of patients that died
during the hospital admission (in-hospital mortality),
LOHS, and costs were also estimated for each year stu-
died. Costs were calculated using Diagnosis-Related
Groups (DRG) for the disease. DRG represents a medical-
economic entity concerning a set of diseases requiring
analogous management resources [18]. All costs shown
are adjusted for the increment of the inflation in the same
period in Spain.
Clinical characteristics included information in overall
co-morbidity at the time of surgery, which was assessed
by computing the Charlson comorbidity index [19]. The
index applies to 19 disease categories that are summated
to obtain an overall score for each patient. We divided
patients into 3 categories: low index, which corresponds
to patients with no previously recorded disease cate-
gories in the Charlson comorbidity index; medium
index, patients with one or two disease categories; and
high index, patients with more than two disease
categories.
The primary diagnosis was considered the reason for
the THA and was categorized in “osteoarthritis (OA)”
and “other reasons”.
Statistical analysis
Quantitative variables are expressed as means, medians,
range and inter-quartile range (IQR). Qualitative variables
are expressed as frequencies and percentages. Compari-
sons were done using the chi-square test, Fisher’se x a c t
test, Student’s t-test, Wilcoxon rank-sum test, ANOVA
or Kruskal-Wallis test as appropriate. The multivariate
analysis of time trend of study variables were conducted
using Poisson and logistic regression models and adjust-
ing by age, sex and other co-variables when appropriate.
We then checked for interactions between the indepen-
dent variables in the regression models. Estimations were
made using STATA version 10.1 program (StataCorp LP,
Lakeway DriveCollege Station, Texas, USA) and statistical
significance was set at two-tailed a < 0 05.
Data were treated with full confidentiality, according
to the Spanish legislation. Patient identifiers were
deleted before the database was provided to the authors
in order to keep strict patient confidentiality. It is not
possible to identify patients at individual levels either in
this paper or in the database. Given the anonymous and
mandatory nature of the data informed consent was not
required nor necessary. The Spanish Ministry of Health
evaluated the protocol of our investigation and consid-
ered that it met all ethical aspects according to the
Spanish legislation so provided us the anonymous
database.
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cal approval was not necessary.
Results
We identified a total of 161,791 discharges of patients
(73,248 men and 88,543 women) having undergone
THA from 2001 to 2008. Table 1 reflects the total num-
ber of procedures performed and the incidence of THA
per 100,000 inhabitants in each year. The overall crude
incidence has increased from 99 THA to 105 THA per
100.000 inhabitants from 2001 to 2008 (p < 0.001).
Among men, incidence significantly increased for all age
categories, except among those aged 65-74 years, where
it decreased. Among women, increase was found among
those aged 75-84 and over 84 years, and decrease was
found in the same age group than in men. Overall, only
men had a significant increase in the crude incidence
over the 8-year study period.
The highest incidence for both sexes was found in the
75-84 years age group. Even more, the highest percent
of increase over time was also seen in this group of
patients. When we compared incidence by sexes we
found higher incidence in women than in men for all
age groups over 64 years and higher incidence among
men for age groups under 65 years.
Time trends in the prevalence of osteoarthritis, dis-
charge destinations and Charlson comorbidity index are
summarized in the Table 2. In 75% of the population
undergoing a THA, osteoarthritis was the main reason
for surgery. After adjusting by age and sex the preva-
lence of OA was found to increase over time.
The proportion of individuals who were discharged to
a social or health institution rose significantly from 3.1%
in 2001 to 4.6% in 2008. In 2001, 81% of patients had a
Charlson Index of 0, 18.4% of 1-2, and 0.6% > 2. In
2008, the proportion of patients who had undergone a
THA and had Charlson Index of 1-2 or >2 had
increased to 20.4% and 1.1% respectively (p < 0.001).
The mean LOHS for THA admissions was 13 days in
2001, but decreased to 10.45 days in 2008 (p < 0.001).
In addition and as expected, it was higher as age
increased. A decreasing time trend in the LOHS was
seen in all age groups (Table 3).
The whole hospital costs for THA hospitalizations in
Spain were 211 millions of Euros in 2008. During the
period studied, the mean cost per patient increased
from 6,634 Euros in 2001 to 9,474 Euros in 2008, which
represents a 42.8% increment (Table 4). Women had a
higher total and mean cost per patient than men in all
the years analyzed.
In-hospital mortality (IHM) rate trends according to
sex- and age-groups are shown in Table 5. The overall
IHM was 0.61% in 2008 (0.55% in women, 0.65% in
men) with the highest mortality rates being among men
and women aged 85 or over, with figures of 6.1% and
3.6% respectively. Women had lower IHM rates than
men in all age groups over 64 years. In fact time trend
analysis shows a significant reduction in IHM among
men aged 65-74 years, 75-84 years and ≥85 years.
Tables 6 and 7 summarizes the results of the multi-
variate analysis. No interactions between independent
variables proved statistically significant. After controlling
Table 1 Age and sex-specific incidence rates for primary THA per 100,000 inhabitants in Spain (2001-8)
2001 2002 2003 2004 2005 2006 2007 2008
Age Sex N = 18,185 N = 19,029 N = 19,545 N = 19,733 N = 20,461 N = 21,176 N = 21,354 N = 22,308 P*
40-54 Men 29.64 31.90 30.83 31.61 33.97 36.62 37.97 39.14 <0.001
Women 17.54 16.92 16.16 16.80 17.93 17.92 17.30 18.20 0.104
50-64 Men 89.80 99.37 97.41 96.92 103.27 104.48 104.53 110.86 <0.001
Women 74.57 78.92 74.77 75.74 69.90 74.03 75.36 75.29 0.420
65-74 Men 200.39 187.94 197.35 189.43 195.56 190.92 192.18 184.98 0.022
Women 217.76 216.53 220.47 206.90 205.14 206.89 199.46 200.96 <0.001
75-84 Men 164.55 192.34 201.86 201.05 209.11 221.16 208.99 226.10 <0.001
Women 214.47 241.82 242.24 256.66 262.51 265.94 262.04 275.89 <0.001
≥ 85 Men 79.25 73.04 81.41 69.09 65.92 78.75 90.63 101.59 <0.001
Women 100.59 102.27 106.43 109.22 112.70 109.87 120.03 119.35 0.008
Total Men 94.64 97.99 99.69 97.52 101.55 103.44 102.87 105.71 <0.001
Women 102.80 106.18 105.48 104.78 104.00 104.83 102.88 105.01 0.931
Both 99.05 102.40 102.80 101.42 102.87 104.19 102.88 105.33 <0.001
Incidence rates calculated by dividing the number of cases per year sex and age group with the corresponding number of person in that population group
according to the National Institute of Statistics (INE) reported at December 31 each year [17].
*P value for time trend estimated using Poisson regression models.
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els, we observed that the incidence of THA hospitaliza-
tions has significantly increased from 2001 to 2008 for
men and women (IRR 1.15, 95% CI 1.11-1.18 and 1.07,
95% CI 1.04-1.09 respectively). With regard to IHM,
after adjusting the logistic regression model, only men
showed a significant reduction in the risk of death after
THA from 2001 to 2008 (OR 0.62 CI 95% 0.43-0.90).
For both sexes the risk of in hospital death was higher
as age and Charlson co-morbidity index increased, and
among those who had other than osteoarthritis as the
reason for surgery. Finally, in the model including both
gender, men had 1.72 times more probabilities of dying
during the hospitalization time for a THA than women.
Discussion
In this observational study involving 161,791 THA, we
found a significant increase in the incidence of this surgi-
cal procedure from 2001 to 2008 in the Spanish popula-
tion. When reporting on incidences of THA, it is
necessary to make comparisons with other countries.
Lohmander et al estimated, among people suffering OA,
the crude incidence of primary THA (rate per year per
100,000 persons) obtaining results between 70 for Iceland
and 99 for Sweden in 2000 [14]. In Australia, Wells et al
obtained an incidence of 60.9 per 100,000 [20]. Our esti-
mated incidence for patients with OA was 74 per
100,000 in 2001 which falls within previously ranges.
However, comparison between studies is too complicated
Table 2 Prevalence of Osteoarthritis, discharge destinations and Charlson comorbidity index of the THA patients in
Spain from 2001 to 2008
2001 2002 2003 2004 2005 2006 2007 2008 P*
Reason for surgery Osteoarthritis (%) 74.8 75.8 75.9 76.1 76.3 76.3 75.4 77.0 <0.001
Other (5) 25,2 24,2 24,1 23,9 23,7 23,7 24,6 23
Discharge destinations Home (%) 96.8 97.0 96.4 96.4 96.1 95.7 95.9 95.3 <0.001
Health/social institution (%) 3.2 3.0 3.6 3.6 3.9 4.3 4.1 4.7
Charlson comorbidity index 0 (%) 81.0 81.2 79.9 79.4 79.2 78.7 77.9 78.5 <0.001
1-2 (%) 18.4 18.1 19.3 19.9 19.9 20.4 21.3 20.4
>2(%) 0.6 0.7 0.8 0.7 0.9 0.9 0.8 1.1
*P value for time trend estimated using logistic regression adjusted by age and sex.
Table 3 Length of stay (LOHS) for primary THA hospitalizations in Spain from 2001 to 2008
2001 2002 2003 2004 2005 2006 2007 2008 P*
Age group LOHS LOHS LOHS LOHS LOHS LOHS LOHS LOHS
40-54* Mean 11.93 11.15 10.84 10.00 9.70 9.69 8.99 9.06 <0.001
Median 10 9 9 88888
IQR 8-13 7-12 7-12 7-11 7-10 6-10 6-9 6-9
50-64* Mean 12.02 11.52 11.29 10.53 10.39 10.10 9.61 9.27 <0.001
Median 11 10 9 98888
IQR 8-14 8-13 8-13 7-12 7-11 7-11 6-10 6-10
65-74* Mean 12.76 12.36 11.75 11.32 10.95 10.67 10.34 10.03 <0.001
Median 11 11 10 99998
IQR 9-14 8-14 8-13 8-13 7-12 7-12 7-11 7-11
75-84 Mean 14.15 13.68 13.31 12.80 12.50 12.31 12.04 11.46 <0.001
Median 12 12 11 11 10 10 9 9
IQR 9-16 9-15 8-15 8-15 8-14 8-14 8-13 7-13
≥ 85 Mean 16.20 17.45 16.67 16.27 15.99 15.11 15.37 14.97 0.001
Median 13 14 13 12 13 12 12 11
IQR 10-18 10-20 10-20 9-18 9-19 9-18 8-18 8-17
Total Mean 13.00 12.61 12.18 11.65 11.36 11.13 10.78 10.45 <0.001
Median 11 11 10 10 9998
IQR 9-15 8-14 8-14 8-13 7-13 7-12 7-12 7-11
IQR Inter quartile range.
* P value for comparing means along the study period.
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graphic structure (age, sex, race), timing of the studies,
and methods of reporting and should be interpreted with
caution [20].
The present results agree with those studies con-
ducted in other countries where females have also sig-
nificantly higher incidence than males [5,7,14,21,22]. In
Spain, females constituted 55% of the patients over the
entire period. In the US, for the period 2000-4 females
accounted for 57% of discharges with diagnosis of total
hip arthroplasty [7]. Analysis of the arthroplasty regis-
tries of Sweden, Denmark, and Norway showed that
females represented 58% of the patients in Denmark,
60% in Sweden, and 70% in Norway [5]. In addition,
female patients had higher incidence rates of THA than
men in all age groups [5]. In Japan, only 16.1% of THA
were conducted in men during 2006-7 period [21]. Pre-
vious research suggests that OA is more prevalent and
incapacitating in females than in males [5,14,22]. Differ-
ences in referral practices and patient willingness or
other unknown factors may explain discrepancies in
THA implantation between gender and differences
between countries in sex-specific incidence [5,14,22].
We also found that men incidence increased signifi-
cantly for all age categories except among those aged
65-74, where decreased. In women, the increase was
found among those aged 75 years and over. In the US,
from 1990 to 2004, the use of THA increased for most
age categories, but unlike the current study, a decrease
in the group of patients over 84 years was seen [7]. We
believe that the increase in older age groups in Spain
m a yb eac o n s e q u e n c eo fc o n c u r r e n ta d v a n c e sd u r i n g
this same time period in surgical techniques, implant
materials and designs and peri-operative care, that has
allowed the extension of surgical indications to older
and sicker patients [9,10,23]. A study conducted in The
Netherlands and Sweden found that only 3% and 15%,
respectively, of increase in THA incidence may be
explained by changes in the population structure by age
[23]. In fact, the results of the Poisson regression
Table 4 Hospital costs for primary total hip arthroplasties hospitalizations in Spain from 2001 to 2008
Year Mean (€) Median (€) Percentile 25 Percentile 75 Total cost (Millions of €)P *
2001 6635 5654 4626 7710 120.65 € <0.001
2002 6731 5889 4283 7495 128.09 €
2003 7418 6145 4916 8603 144.98 €
2004 7654 6309 5232 8502 151.03 €
2005 7345 5890 4581 8404 150.28 €
2006 8754 7107 5528 9476 185.37 €
2007 8625 7234 5626 9645 184.19 €
2008 9474 7297 6385 10034 211.34 €
* P value for comparing means along the study period.
Table 5 Incidence of In-Hospital Mortality (IHM) after primary THA in Spain from 2001 to 2008
2001 2002 2003 2004 2005 2006 2007 2008
IHM (%) IHM (%) IHM (%) IHM (%) IHM (%) IHM (%) IHM (%) IHM (%) p*
40-54 Men 0.00 0.16 0.24 0.15 0.00 0.06 0.17 0.11 0.924
Women 0.15 0.44 0.00 0.70 0.00 0.13 0.00 0.23 0.367
50-64 Men 0.23 0.21 0.46 0.10 0.05 0.13 0.21 0.16 0.239
Women 0.06 0.06 0.06 0.06 0.13 0.12 0.28 0.27 0.018
65-74 Men 0.49 0.49 0.41 0.18 0.39 0.34 0.31 0.19 0.025
Women 0.27 0.47 0.22 0.40 0.26 0.24 0.40 0.30 0.884
75-84 Men 1.68 1.66 1.41 0.80 0.97 1.10 1.26 1.05 0.046
Women 0.77 0.84 0.52 1.06 0.70 0.87 0.69 0.71 0.736
≥ 85 Men 8.75 8.28 3.91 9.55 5.73 5.53 4.90 6.10 0.004
Women 3.85 3.78 5.97 5.63 5.25 3.70 5.45 3.60 0.435
Total Men 0.75 0.76 0.69 0.47 0.47 0.53 0.60 0.55 0.511
Women 0.54 0.68 0.57 0.87 0.66 0.63 0.78 0.65 0.722
Both 0.63 0.71 0.62 0.69 0.57 0.59 0.69 0.61 0.479
IHD is calculated dividing the number of death by the number of THA hospitalizations in that sex and age group.
*P value for time trend estimated using Poisson regression models.
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THA in men and also in women became significant
after adjusting for potential confounders. Other authors
using multivariate models have reached the same con-
clusions, verifying therefore that the increase in inci-
dence of THA is not only a consequence of the
population growth or ageing [7,9-11].
Primary osteoarthritis, as the most frequent diagnosis
among THA patients is constantly found in Europe and
elsewhere [5,13,14,21]. Havelin et al showed prevalence
of OA of 77.6% in Denmark, 78.8% in Sweden and
73.7% in Norway [5] values almost identical to those
reported in the current study for Spain. In Japan, 80.6%
of the patients who received THA during 2006-7 have
been diagnosed of OA [21].
In Spain, the number of high-risk surgical patients has
increased over last 8 years as shown by the analysis of
Charlson comorbidity index. This same trend has been
previously described in other studies [7,9,10,21]. Aging
of population will undoubtedly make patient manage-
ment after THA more complex in the future [7,9,10,21].
Even more, this increase in co-morbidities in THA
patients after adjusting by age, reflect the declining
health status of the general Spanish population as pre-
viously suggested [24-26].
The LOHS decreased signficantly from an average of
13 days in 2001 to 10.45 days in 2008 in Spain. The mean
nationwide LOHS for Spain is longer than that described
in other countries such as Denmark, USA or Taiwan, but
shorter than in Japan [7,9,21,27,28]. Reasons for the
decrease in the LOHS overtime suggested by other
authors that may be well applies to Spain include: more
specialized departments with multidisciplinary and multi-
modal teams using more efficient means to rehabilitate
and discharge patients and, as found in our study, the
increased rate of discharges to short and long-term care
facilities [7,13,27,28]. The trend of hospital discharges to
medium-care institutions may reflect the indiosincratic
problem of a Public Health System. Neither patients
accept nor doctors promote a complete discharge until the
patient has recovered a certain degree of autonomy as they
are not directly penalty by the cost of the procedure.
In all the years analyzed most THA admissions were
elective (82-84%) with the remaining 16-18% through
the emergency room. The changes in these proportions
showed no significant time trend.
Table 6 Multivariate analysis of trends and factors associated with incidence for primary THA
INCIDENCE OF HOSPITALIZATIONS FOR THA
Risk Rate Ratios (95% Confidence Intervals)*
Men Women Both
Age 40-54 - - -
55-64 2.96 (2.89-3.03) 4.30 (4.17-4.43) 3.40 (3.34-3.46)
65-74 5.65 (5.52-5.77) 12.04 (11.71-12.38) 7.84 (7.71-7.97)
75-84 5.98 (5.84-6.12) 14.57 (14.17-14.98) 9.09 (8.93-9.25)
≥85 2.37 (2.25-2.50) 6.37 (6.14-6.21) 3.97 (3.86-4.08)
Sex Women NA NA -
Men NA NA 1.03 (1.02-1.04)
Reason for surgery OA - - -
Other 0,21 (0,20-0,22) 0,42 (0,41-0,43) 0,32 (0,31-0,33)
Charlson comorbidity index 0 - - -
1-2 0.24 (0.24-0.25) 0.25 (0.25-0.26) 0.25 (0.24-0.25)
>2 0.012 (0.011-0.013) 0.008 (0.008-0.009) 0.010 (0.009-0.011)
YEAR 2001 - - -
2002 1.04 (1.00-1.07) 1.04 (1.01-1.07) 1.04 (1.02-1.06)
2003 1.06 (1.03-1.09) 1.04 (1.01-1.07) 1.05 (1.03-1.07)
2004 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.02-1.06)
2005 1.09 (1.06-1.12) 1.04 (1.01-1.07) 1.06 (1.04-1.08)
2006 1.11 (1.08-1.15) 1.05 (1.02-1.08) 1.08 (1.06-1.10)
2007 1.11 (1.08-1.15) 1.04 (1.01-1.07) 1.07 (1.05-1.09)
2008 1.15 (1.11-1.18) 1.07 (1.04-1.09) 1.10 (1.08-1.12)
Calculated using multivariate Poisson regression Dependent variable “Incidence of hospitalizations for THA”.
The independent variables included in the models are those shown in the table.
OA Osteoarthritis.
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from 120.65 millions of Euros in 2001 to 211.34 millions
in year 2008, this represents a 75% increase. The average
cost per patient has risen from 6,634 Euros in 2001 to
9,473 Euros in 2008 (42.8% increment). In France whole
hospital cost for primary joint replacement for coxar-
throsis (N = 69,948) was 590.6 millions of Euros in
2004, with a mean cost per patient of 8,318 Euros [13].
A recent study comparing the cost of primary hip repla-
cement within 9 member states of the European Union
found that the total cost of treatment per patient ranged
from 1,290 Euros (Hungary) to 8,739 Euros (The Neth-
erlands) [12]. The charge in the USA has been found to
be higher [29]. In any case, and as previously commen-
ted, comparison of LOHS and costs between countries
is too difficult because differences in demographics and
specific healthcare system organization and financing
[12,13].
A striking result of our study is that, despite the
reduction in LOHS, the cost has increased. We believe
that this finding may be associated with greater inci-
dence of risk factors and comorbidities in THA patients,
higher cost of surgical materials and postoperative care,
or an increase in cost of fee-for-service [10,29].
Furthermore, the fact that in Spain the payment system
to hospitals has been increasingly associated with the
complexity of the patients treated, may have led hospitals
to prioritize the codification of those diseases that are
associated with increases in the LOHS and in-hospital
mortality [10].
The overall in-hospital mortality (IHM) after primary
THA in Spain ranged from 0.71% to 0.59% over 2001-
08. These findings are higher than those reported in
other countries [7,21,27]. Doro et al analyzed
275,813 primary THA for OA from 1988 to 2000 using
the US Nationwide Inpatient Sample database and
observed that in-hospital mortality was 0.16% in the
highest volume hospitals and 0.29% in the lowest
volume [27]. More recently, and using the same data-
base, Liu et al have described an in-hospital mortality
rate of 0.29% in the 2000-2004 period (n = 953,130) for
all primary THA beside the diagnosis [7]. In Japan, a
report including 13, 537 THA conducted in 2006-7,
found an IHM of 0.23% [21]. Allepuz A et al, using a
method similar to ours described almost identical IHM
for Catalonia (Spain) in the period 200-2005 [10].
Considering that comparisons are not possible due to
the differences in patients and system characteristics,
Table 7 Multivariate analysis of trends and factors associated with in-hospital deaths after primary THA
IN-HOSPITAL DEATHS AFTER HOSPITALIZATIONS FOR THA
Odds Ratios (95% Confidence Intervals
Men Women Both
Age 40-54 - - -
55-64 2.16 (1.13-4.14) 0.76 (0.37-1.59) 1.49 (0.92-2.41)
65-74 4.29 (2.39-7.71) 1.61 (0.88-2.93) 3.10 (2.03-4.71)
75-84 11.81 (6.70-20.82) 2.95 (1.65-5.29) 6.81 (4.52-10.25)
≥85 28.25 (15.67-50.91) 10.45 (5.81-18.80) 20.83 (13.74-31.58)
Sex Women NA NA -
Men NA NA 1.72 (1.50-2.01)
Reason for surgery OA - - -
Other 6,67 (5,26-8,33) 5,56 (4,35-6,67) 5,88 (5,00-7,14)
Charlson comorbidity index 0 - - -
1-2 4.40 (3.54-5.47) 4.38 (3.66-5.24) 4.39 (3.82-5.04)
>2 18.20 (12.93-25.63) 17.78 (12.78-24.73) 18.08 (14.28-22.89)
YEAR 2001 - - -
2002 0.97 (0.67-1.40) 1.30 (0.91-1.86) 1.13 (0.88-1.46)
2003 0.81 (0.56-1.17) 0.99 (0.69-1.45) 0.91 (0.70-1.18)
2004 0.57 (0.38-0.86) 1.56 (1.11-2.20) 1.04 (0.81-1.34)
2005 0.53 (0.36-0.80) 1.13 (0.79-1.62) 0.82 (0.63-1.07)
2006 0.57 (0.39-0.84) 1.07 (0.75-1.54) 0.81 (0.62-1.05)
2007 0.59 (0.41-0.86) 1.20 (0.85-1.70) 0.88 (0.68-1.13)
2008 0.54 (0.37-0.79) 1.04 (0.73-1.48) 0.78 (0.60-1.00)
Calculate using logistic regression. Dependent variable “In hospital death after hospitalizations for THA”.
The independent variables included in the models are those shown in the table. OA Osteoarthritis.
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Page 7 of 9the results of the present study call for urgent research
assessing the reasons for such high mortality in Spain.
The large number of surgeries conduced in the oldest
patients (≥85 years) that has increased sharply in last
years is surely contributing to this high IHM. Future
studies are needed to confirm this assumption.
Results from the regression analysis show that over the
entire period, men exhibited 72% more probability of
dying as a consequence of THA than women. Further,
the risk of death also increased with age, number of com-
morbid conditions and having other than OA as reason
for THA. These finding are consistent with previous stu-
dies showing that the most important risk factors for
excessive early postoperative mortality for THA are male
gender, older age and co-morbidity [7,15,27].
Finally, we found that increased incidence of THAs
was coupled with a slightly reduced rate of in-hospital
mortality among men, which is similar to previous
reports [7]. Beside those factors previoully commented
expaining the increased incidence of THA and the
reduction in the LOHS, we agree with others that the
increased volume and the use of THAs in-itself has pos-
sibly helped to reduce mortality [7,27,30,31].
We should recognize strengths and limitations of the
current study. The main strength of the current study
lies in a large sample size and standardized methodology
maintained constant along the study period. Futhremore,
discharge databases have been widely used by other
authors to assess outcomes, burden and trends of THA
[7,10,13,15,21,27]. Nevertheless, our study presents some
limitations. Firstly, a potential source of bias comes from
relying on administrative registries as several discrepan-
cies between administrative data and audited and vali-
dated clinical data have been suggested [32-35]. However,
others have reported that this information was fairly reli-
able [32-35]. Even more, coding may have improved over
the study period resulting in higher comorbidities [10].
Secondly, outcomes were limited to the variables coded,
which do not include relevant data such as type of pros-
thesis fixation, pharmacologic treatments or other factors
such as function and pain relief, among others. Therefore,
outcomes as LOHS and discharge destination may have
been influenced by other covariates different from post-
operative complications. In such scenario, only in-hospital
mortality can be used to draw direct conclusions on the
complication rate in the curren study [27]. Thirdly, we
only focused on hospital admissions in people aged over
40 years. Indeed, hospitalizations in people aged under
40 years represented < 2% of all hospitalizations for THA
in Spain and other countries [5,10,13]. Lastly, the data in
the CMBD is anonymous, with the result that it is impos-
sible to trace patients who underwent a contralateral pro-
cedure during the same period. Despite these limitations,
the CMBD discharge database has the advantage of being
mandated by the National Public Health System and it
includes almost 100% of admissions in Spain [16]. In
addition, Spain is a large country with a public heatlh
system providing full free of charge medical and surgical
services to the entire population, so patients came from a
variety of socioeconomic categories improving the exter-
nal validity of the current results.
In our opinion, the best option to obtain more
extense, reliable and accuarate information would be to
create a national arthroplasty register like is already
available in other European countries and Australia
[5,14,20]. Implating registries are also necessarry as a
surveillence system that would allow tracing new models
and early idenfication and withdrow of those with worse
results than previous models. In the absence of a formal
domestic registry, the incidence, IHM rates and cost
estimation reported in this study provide the best possi-
ble available information.
Conclusions
The current study provides clear and valid data indicat-
ing an increase in incidence of primary THA in Spain
from 2001 to 2008 with concomitant reductions in
LOHS and slight reduction in-hospital mortality, but a
significant increase in cost per patient. The health pro-
f i l eo ft h ep a t i e n tu n d e r g o i n gaT H As e e m st ob ew o r -
sening in Spain. This time trend may be useful for
planning future resources, e.g. surgical and rehabilitation
centers or specialist consultations.
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